trial

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode

NCTId NCT04203056
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 15 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2022-10-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
15 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2019-12-16
Primary completion
2022-10-01
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
AripiprazoleARI-ORALAL-NCD

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor
Alkermes, Inc.Collaborator

Investigators

1
Kenneth L Subotnik, PhDPrincipal Investigator

Sites

1 total
Los Angeles, United States

Facts & assertions

4 sourced
Enrollment
15
Phase
PHASE4
Primary Completion Date
2022-10-01
Status
TERMINATED
relationships
The graph out of here
drug
Aripiprazole
drug
ARI-ORAL
drug
AL-NCD
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
collaborator
Alkermes, Inc.
company
indication
Schizophreniform Disorder
indication
Psychotic Disorders
indication
Schizophrenia
indication
investigator
Kenneth L Subotnik, PhD
person